Pulmonary Fibrosis Treatment Market Controlled by Two Key Manufacturers
The pulmonary fibrosis treatment marketis dominated by two key global manufacturers. Pharmaceutical & biopharmaceutical companies Genentech Inc. and Boehringer Ingelheim International GmbH control the global pulmonary fibrosis treatment market by generating over 90%of the revenue.
Manufacturers of pulmonary fibrosis treatment drugs are mainly competing on the basis of geographical product footprint, collaborations for developing new drugs as well as to increase the geographical reach, superior efficacy of the product, etc. These two manufacturers are mostly engaging in pipeline development, drug launches, collaborations and partnerships to enhance their revenue generation across the world. For example, in July 2019,Boehringer Ingelheim entered into collaboration and license agreement with Bridge Biotherapeutics to strengthen its Idiopathic Pulmonary Fibrosis (IPF) Pipeline.
Find Out More about the Report Coverage
- Genentech, Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Ltd.
- Alkem Laboratories Ltd.
- Alniche Life Sciences Pvt Ltd
- MHS Pharmaceuticals
- Torrent Pharmaceuticals Ltd
- Anthem Biopharma Pvt Ltd
- Panacea Biotec
- Zydus Healthcare Ltd
- Nuper Therapeutics
- Fresenius Kabi India Pvt Ltd.
- Sun Pharmaceutical Industries Ltd
Drug Approvals and Launches
Apart from traditional off-label corticosteroid treatment options, drugs such as Ofev (nintedanib) by Boehringer Ingelheim Pharmaceuticals, Inc. and Esbriet (Pirfenidone) by Genentech Inc. received marketing approval in 2014 changing the dynamics of the pulmonary fibrosis treatment market.
Similarly, various companies are applying for FDA approval or orphan drug designation for their respective products such as, In August 2019, EmphyCorp Inc. applied for NDA marketing application for its non-steroidal nasal spray for the treatment of Interstitial Lung Diseases (ILD), which includes pulmonary fibrosis and cystic fibrosis.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Breakthrough Therapies for Effective Treatment of Pulmonary Fibrosis
The cause of the pulmonary fibrosis is unknown making the treatment options limited. The development of novel therapies for the pulmonary fibrosis treatment are majorly halt by the lack of understanding of the prognosis of the disease. Various organizations, universities, pharmaceutical and biopharmaceutical companies are awarding grants, fellowships for the possible invention of the causative factor as well as breakthrough therapy.
For example, in 2017, National Heart, Lung, and Blood Institute of the National Institutes of Health grant awarded over US$ 2.1 million to Weill Cornell Medicine researchers for the span of over 4 years to find out the mechanism causing scar tissues in lungs.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Ageing Population Increasing Opportunities for the Market
The chances of developing pulmonary fibrosis increases significantly with the increasing age. As per the Pulmonary Fibrosis Foundation, more than 80% of cases of pulmonary fibrosis are in people aged above 40 years.
The patient who are at risk of developing pulmonary fibrosis can develop the disease with slight exposure to trigger factors. Age plays a major role in initiating or preventing the onset of disease.
Increasing availability of novel therapies for the treatment of various diseases resulting in increased life expectancy and decreasing fertility rate across the world is expected to impact the higher population aged above 60 years as compared to children below 10 years by the end of 2030 (United Nations Estimate). Currently, more than 66% of people aged over 60 years are living in the developing region and the number is growing rapidly as compared to the developed region.
Explore Persistence Market Research’s expertise in promulgation of the business !
Pulmonary fibrosis treatment Market: Competitive Landscape
This part of the report consists of the profiles of key players in the pulmonary fibrosis treatment market based on their market shares, product offerings, differential strategies, marketing approach, and company dashboard. Some of the important players featured in the pulmonary fibrosis treatment market report include Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., and others.
Pulmonary fibrosis treatment: Definition
Pulmonary fibrosis is interstitial lung disease in which the scarring of the lung tissue starts reducing the oxygen exchange area of the lungs. It is non-reversible disease and cannot be cured. Pulmonary fibrosis treatment drugs can help with the management of the disease for span of around 2 to 5 years.
Pulmonary fibrosis treatment Market: About the Report
The company conducted a research study on the pulmonary fibrosis treatment market for the forecast period 2019-2029. The report offers a comprehensive evaluation of the business opportunities available in the pulmonary fibrosis treatment market, with insights on the current trends, reimbursements, as well as regulatory scenario in the pulmonary fibrosis treatment market.
Pulmonary fibrosis treatment Market: Segmentation
The report offers a comprehensive taxonomy of the market based on the therapy type, indication, distribution channel, and region. By therapy type, the pulmonary fibrosis treatment market is segmented into monotherapy, combination therapy and symptomatic treatment.
By indication, the pulmonary fibrosis treatment market is segmented as idiopathic pulmonary fibrosis, familial pulmonary fibrosis and others. By distribution channel, the pulmonary fibrosis treatment market is segmented into hospital pharmacies, retail pharmacies and mail order pharmacies.
The pulmonary fibrosis treatment market has been analyzed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA).
Additional Questions Answered
Some of the additional questions addressed in this report on the pulmonary fibrosis treatment market:
- What is the overall revenue generation potential of the pulmonary fibrosis treatment market across all regions?
- Who are the key regional and global competitors? What are their portfolios in the pulmonary fibrosis treatment market?
- What are the major challenges influencing the growth of the pulmonary fibrosis treatment market?
- What are the breakthrough therapies arriving in the market during the forecast period?
The market has been estimated based on a supply-demand approach. The market was first calculated based on the prevalence, diagnosis rate and treatment cost using pulmonary fibrosis treatment drugs in different regions/countries.
Some of the other qualitative factors analyzed include the awareness level and the availability of pulmonary fibrosis treatment. This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions, and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals, and resourceful databases).
The research study on the pulmonary fibrosis treatment market also includes the top trends and the macro- as well as micro-economic factors shaping the pulmonary fibrosis treatment market. With this approach, the report on the pulmonary fibrosis treatment market estimates the industry attractiveness of every major segment in the market over the forecast period.